Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 233

recruiting
3 977
countries
28
conditions
2 105

3 664 trials match your criteria

Colon cancer stage II+1

Not recruiting

Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Non-small cell lung cancer stage III

Not recruiting

Study on Radiotherapy and Durvalumab for Patients with Resectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Acromegaly

Not recruiting

Study of long-term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Octreotide Hydrochloride

Neoplasm

Not recruiting

Study for Patients with Advanced Cancer Continuing Ribociclib Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nazartinib

Hepato-lenticular degeneration

Not recruiting

Study on Gene Therapy with VTX-801 and Copper (64Cu) Chloride for Adults with Wilson's Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Adeno-Associated Viral Vector Serotype 3B Encoding Shortened Human Atp7B

Neuroblastoma+4

Not recruiting

Study on Ribociclib, Topotecan, and Temozolomide for Children and Young Adults (12 months - 21 years) with Relapsed or Refractory Neuroblastoma and Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Ribociclib

Hepatocellular carcinoma

Not recruiting

Study of Durvalumab, Tremelimumab, and Lenvatinib with TACE for Patients with Liver Cancer (Hepatocellular Carcinoma)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Hereditary angioedema

Not recruiting

Study on Long-Term Safety of Donidalorsen for Patients with Hereditary Angioedema

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Donidalorsen

Diffuse large B-cell lymphoma

Not recruiting

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Idiopathic pulmonary fibrosis

Not recruiting

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550

Colorectal cancer metastatic

Not recruiting

Study Comparing Sacituzumab Govitecan with Standard Treatment for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Myotonic dystrophy

Not recruiting

Safety and effectiveness study of DYNE-101 in patients with Myotonic Dystrophy Type 1 (DM1)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Humanised Igg1 Kappa Fragment Antibody Targeting Tfr1 Conjugated To P125 Oligonucleotide

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.